NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02120417 2018-02-13A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerIncyte CorporationPhase 2 Terminated149 enrolled 14 charts
NCT01562873 2017-02-23Ruxolitinib in Patients With Breast CancerDana-Farber Cancer InstitutePhase 2 Terminated21 enrolled 7 charts